552 related articles for article (PubMed ID: 34350691)
1. Eight-year follow-up outcome of subthalamic deep brain stimulation for Parkinson's disease: Maintenance of therapeutic efficacy with a relatively low levodopa dosage and stimulation intensity.
Jiang L; Chen W; Guo Q; Yang C; Gu J; Xian W; Liu Y; Zheng Y; Ye J; Xu S; Hu Y; Wu L; Chen J; Qian H; Fu X; Liu J; Chen L
CNS Neurosci Ther; 2021 Nov; 27(11):1366-1373. PubMed ID: 34350691
[TBL] [Abstract][Full Text] [Related]
2. EuroInf 2: Subthalamic stimulation, apomorphine, and levodopa infusion in Parkinson's disease.
Dafsari HS; Martinez-Martin P; Rizos A; Trost M; Dos Santos Ghilardi MG; Reddy P; Sauerbier A; Petry-Schmelzer JN; Kramberger M; Borgemeester RWK; Barbe MT; Ashkan K; Silverdale M; Evans J; Odin P; Fonoff ET; Fink GR; Henriksen T; Ebersbach G; Pirtošek Z; Visser-Vandewalle V; Antonini A; Timmermann L; Ray Chaudhuri K;
Mov Disord; 2019 Mar; 34(3):353-365. PubMed ID: 30719763
[TBL] [Abstract][Full Text] [Related]
3. Long-term Efficacy of Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease: A 5-year Follow-up Study in China.
Jiang LL; Liu JL; Fu XL; Xian WB; Gu J; Liu YM; Ye J; Chen J; Qian H; Xu SH; Pei Z; Chen L
Chin Med J (Engl); 2015 Sep; 128(18):2433-8. PubMed ID: 26365958
[TBL] [Abstract][Full Text] [Related]
4. Nonmotor symptoms evolution during 24 months of bilateral subthalamic stimulation in Parkinson's disease.
Dafsari HS; Silverdale M; Strack M; Rizos A; Ashkan K; Mahlstedt P; Sachse L; Steffen J; Dembek TA; Visser-Vandewalle V; Evans J; Antonini A; Martinez-Martin P; Ray-Chaudhuri K; Timmermann L;
Mov Disord; 2018 Mar; 33(3):421-430. PubMed ID: 29465787
[TBL] [Abstract][Full Text] [Related]
5. Subthalamic Nucleus Deep Brain Stimulation Modulate Catecholamine Levels with Significant Relations to Clinical Outcome after Surgery in Patients with Parkinson's Disease.
Yamamoto T; Uchiyama T; Higuchi Y; Asahina M; Hirano S; Yamanaka Y; Kuwabara S
PLoS One; 2015; 10(9):e0138462. PubMed ID: 26394059
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcomes using ClearPoint interventional MRI for deep brain stimulation lead placement in Parkinson's disease.
Ostrem JL; Ziman N; Galifianakis NB; Starr PA; Luciano MS; Katz M; Racine CA; Martin AJ; Markun LC; Larson PS
J Neurosurg; 2016 Apr; 124(4):908-16. PubMed ID: 26495947
[TBL] [Abstract][Full Text] [Related]
7. Beneficial nonmotor effects of subthalamic and pallidal neurostimulation in Parkinson's disease.
Dafsari HS; Dos Santos Ghilardi MG; Visser-Vandewalle V; Rizos A; Ashkan K; Silverdale M; Evans J; Martinez RCR; Cury RG; Jost ST; Barbe MT; Fink GR; Antonini A; Ray-Chaudhuri K; Martinez-Martin P; Fonoff ET; Timmermann L;
Brain Stimul; 2020; 13(6):1697-1705. PubMed ID: 33038595
[TBL] [Abstract][Full Text] [Related]
8. Relationship between electrode position of deep brain stimulation and motor symptoms of Parkinson's disease.
Zhang F; Wang F; Li W; Wang N; Han C; Fan S; Li P; Xu L; Zhang J; Meng F
BMC Neurol; 2021 Mar; 21(1):122. PubMed ID: 33731033
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcomes following awake and asleep deep brain stimulation for Parkinson disease.
Chen T; Mirzadeh Z; Chapple KM; Lambert M; Shill HA; Moguel-Cobos G; Tröster AI; Dhall R; Ponce FA
J Neurosurg; 2018 Mar; 130(1):109-120. PubMed ID: 29547091
[TBL] [Abstract][Full Text] [Related]
10. Long-term impact on quality of life of subthalamic nucleus stimulation in Parkinson's disease.
Lezcano E; Gómez-Esteban JC; Tijero B; Bilbao G; Lambarri I; Rodriguez O; Villoria R; Dolado A; Berganzo K; Molano A; de Gopegui ER; Pomposo I; Gabilondo I; Zarranz JJ
J Neurol; 2016 May; 263(5):895-905. PubMed ID: 26964542
[TBL] [Abstract][Full Text] [Related]
11. Meta-analysis comparing deep brain stimulation of the globus pallidus and subthalamic nucleus to treat advanced Parkinson disease.
Liu Y; Li W; Tan C; Liu X; Wang X; Gui Y; Qin L; Deng F; Hu C; Chen L
J Neurosurg; 2014 Sep; 121(3):709-18. PubMed ID: 24905564
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Awake vs. Asleep Surgery for Subthalamic Deep Brain Stimulation in Parkinson's Disease.
Blasberg F; Wojtecki L; Elben S; Slotty PJ; Vesper J; Schnitzler A; Groiss SJ
Neuromodulation; 2018 Aug; 21(6):541-547. PubMed ID: 29532560
[TBL] [Abstract][Full Text] [Related]
13. Predictive Factors of Antiparkinsonian Drug Reduction after Subthalamic Stimulation for Parkinson's Disease.
Samura K; Miyagi Y; Kawaguchi M; Yoshida F; Okamoto T; Kawashima M
Neurol Med Chir (Tokyo); 2019 Sep; 59(9):331-336. PubMed ID: 31231086
[TBL] [Abstract][Full Text] [Related]
14. Long-term outcome of young onset Parkinson's disease after subthalamic stimulation--a cross-sectional study.
Tsai ST; Hung HY; Hsieh TC; Lin SH; Lin SZ; Chen SY
Clin Neurol Neurosurg; 2013 Oct; 115(10):2082-7. PubMed ID: 23916724
[TBL] [Abstract][Full Text] [Related]
15. A comparison of indirect and direct targeted STN DBS in the treatment of Parkinson's disease-surgical method and clinical outcome over 15-year timespan.
Lahtinen MJ; Haapaniemi TH; Kauppinen MT; Salokorpi N; Heikkinen ER; Katisko JP
Acta Neurochir (Wien); 2020 May; 162(5):1067-1076. PubMed ID: 32103343
[TBL] [Abstract][Full Text] [Related]
16. Deep Brain Stimulation in Patients with Parkinson's Disease: Effect on Psychiatric Symptoms and Quality of Life.
Seijo Zazo E; Fernandez FS; Liebana ES; Ayala AS; Aragoneses BL; Campa JMT; Portilla PG; Vega MA
J Neurol Surg A Cent Eur Neurosurg; 2018 Mar; 79(2):130-138. PubMed ID: 28962066
[TBL] [Abstract][Full Text] [Related]
17. A prospective, controlled study of non-motor effects of subthalamic stimulation in Parkinson's disease: results at the 36-month follow-up.
Jost ST; Sauerbier A; Visser-Vandewalle V; Ashkan K; Silverdale M; Evans J; Loehrer PA; Rizos A; Petry-Schmelzer JN; Reker P; Fink GR; Franklin J; Samuel M; Schnitzler A; Barbe MT; Antonini A; Martinez-Martin P; Timmermann L; Ray-Chaudhuri K; Dafsari HS;
J Neurol Neurosurg Psychiatry; 2020 Jul; 91(7):687-694. PubMed ID: 32371534
[TBL] [Abstract][Full Text] [Related]
18. Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up.
Rodriguez-Oroz MC; Obeso JA; Lang AE; Houeto JL; Pollak P; Rehncrona S; Kulisevsky J; Albanese A; Volkmann J; Hariz MI; Quinn NP; Speelman JD; Guridi J; Zamarbide I; Gironell A; Molet J; Pascual-Sedano B; Pidoux B; Bonnet AM; Agid Y; Xie J; Benabid AL; Lozano AM; Saint-Cyr J; Romito L; Contarino MF; Scerrati M; Fraix V; Van Blercom N
Brain; 2005 Oct; 128(Pt 10):2240-9. PubMed ID: 15975946
[TBL] [Abstract][Full Text] [Related]
19. The medical treatment of patients with Parkinson's disease receiving subthalamic neurostimulation.
Alexoudi A; Shalash A; Knudsen K; Witt K; Mehdorn M; Volkmann J; Deuschl G
Parkinsonism Relat Disord; 2015 Jun; 21(6):555-60; discussion 555. PubMed ID: 25842260
[TBL] [Abstract][Full Text] [Related]
20. Subthalamic deep brain stimulation and levodopa in Parkinson's disease: a meta-analysis of combined effects.
Vizcarra JA; Situ-Kcomt M; Artusi CA; Duker AP; Lopiano L; Okun MS; Espay AJ; Merola A
J Neurol; 2019 Feb; 266(2):289-297. PubMed ID: 29909467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
